Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer
Combinational Therapy of Capecitabine, Lapatinib and Vinorelbine for the Treatment of Patients With her2/Neu Positive, Relapsed or Metastatic Breast Carcinoma Following Treatment Failure With Trastuzumab
Sponsor: Arbeitsgemeinschaft fur Internistische Onkologie
A PHASE1 clinical study on Failure or Contraindication of Trastuzumab Therapy and First or Second Line Therapy, this trial is terminated or withdrawn. The trial is conducted by Arbeitsgemeinschaft fur Internistische Onkologie and has accumulated 6 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arbeitsgemeinschaft fur Internistische Onkologie
- Arbeitskreis Klinische Studien
- GlaxoSmithKline
- Sponsor GmbH
- iOMEDICO AG
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Dresden, Germany, Goslar, Germany, Gütersloh, Germany, Heidelberg, Germany, Kassel, Germany, Leer, Germany, Mülheim, Germany, Münster, Germany, Neuss, Germany, Ravensburg, Germany and 1 more location